3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
COVID-19
2
Severe Acute Respiratory Syndrome
1
Papillomavirus Infections
1
Multiple Myeloma
1
Mastocytosis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypersensitivity
1
Interventions
Dexamethasone
242
Lenalidomide
147
daratumumab
125
Bortezomib
102
pomalidomide
88
Calcium Dobesilate
76
carfilzomib
75
Cyclophosphamide
71
Specimen Handling
42
isatuximab
41
Biopsy
40
belantamab mafodotin
37
fludarabine
36
Magnetic Resonance Spectroscopy
35
talquetamab
29
Melphalan
28
dexamethasone acetate
27
dexamethasone 21-phosphate
27
auricularum
26
iberdomide
25
ixazomib
22
fludarabine phosphate
22
selinexor
21
elotuzumab
21
Whole-Body Irradiation
14
X-Rays
13
tocilizumab
12
venetoclax
11
Mycophenolic Acid
10
trametinib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
2019-nCoV Vaccine mRNA-1273
×
1 year
×
Clear all
NCT05556720
2025-10-03
BOOST-IC
Monash University
Phase 3
Active not recruiting
960 enrolled